RecallRadar

FDA Drug recall D-0003-2023

Aminophylline Injection, USP 250 mg/10 mL (25 mg/mL) 25x10 mL Single-dose vial, Rx only, Distributed by Hospira, Inc

On 2022-10-12 the FDA classified a Class II recall of Aminophylline Injection, USP 250 mg/10 mL (25 mg/mL) 25x10 mL Single-dose vial, Rx only, Distributed by Hospira, Inc by Pfizer, citing presence of Particulate Matter: A complaint was received for the presence of a hair in one vial.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0003-2023
ClassificationClass II
Statusterminated
Initiated2022-09-27
Published2022-10-12
Last updated2026-09-13 11:52 UTC
CompanyPfizer
DistributionPR

Product

Aminophylline Injection, USP 250 mg/10 mL (25 mg/mL) 25x10 mL Single-dose vial, Rx only, Distributed by Hospira, Inc. Lake Forest, IL 60045 USA. NDC 0409-5921-16 (vial) 0409-5921-01 (carton)

Reason

Presence of Particulate Matter: A complaint was received for the presence of a hair in one vial.

Identifiers

ndc0409-5921-16
ndc0409-5921-01
ndc0409-5922-16
ndc0409-5922-01
code_infoLot: 30-137-DK Exp. 1 DEC. 2022

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0003-2023%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.